09-11-00

A

Docket No. 60467/JPW/EMW

September 8, 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Honorable Assistant Commissioner for Patents
Washington, D.C. 20231

S I R:

Transmitted herewith for filing are the specification and claims of the patent application of:

Samuel C. Silverstein, John D. Loike and Francesco DiVirgilio for

Inventor(s) A NOVEL METHOD FOR USING PHAGOCYTIC PARTICLES AND ATP RECEPTORS TO DELIVER ANTIGENS TO MHC CLASS I RECEPTORS TO INDUCE IMMUNITY AGAINST MICROBIAL PATHOGENS OR TUMORS OR TO SUPPRESS IMMUNITY
Title of Invention

Also enclosed are:

X 5 sheet(s) of ____informal X formal drawings.

X Oath or declaration of Applicant(s). (unsigned)

X A power of attorney

____ An assignment of the invention to _____

X A Preliminary Amendment

X A verified statement to establish small entity status under 37 C.F.R. §1.9 and §1.27.

The filing fee is calculated as follows:

CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT

	NUMBER FILED		NUMBER EXTRA*		RATE SMALL ENTITY	RATE OTHER ENTITY		FEE SMALL ENTITY	FEE OTHER ENTITY
Total Claims	32 -20	=	12	X	$ 9.00	$18.00	=	$	$ 216
Independent Claims	2 -3	=	0	X	$39.00	$78.00	=	$	$ 0
Multiple Dependent Claims Presented: ____Yes X No					$130.00	$260.00	=	$	$
						BASIC FEE		$ 345	$ 690
						TOTAL FEE		$	$ 906.00

*If the different in Col. 1 is less than zero, enter "0" in Col. 2

X A check in the amount of $ 906.00 to cover the filing fee.

____ Please charge Deposit Account No. _____ in the amount of $_____.

X The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the following or credit any over-payment to Account No. 03-3125:

X Filing fees under 37 C.F.R. §1.16.

X Patent application processing fees under 37 C.F.R. §1.17.

____ The issue fee set in 37 C.F.R. §1.18 at or before mailing of the Notice of Allowance, pursuant to 37 C.F.R. §1.311(b).

X Three copies of this sheet are enclosed.

____ A certified copy of previously filed foreign application No. _____ _____ filed in _____ on _____. Applicant(s) hereby claim priority based upon this aforementioned foreign application under 35 U.S.C. §119.

X Other (identify) Express Mail Certificate of Mailing bearing Label No. EK 166 980 907 US dated September 8, 2000, a loose set of formal drawings (5 sheets).

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

Dkt. 60467/JPW/EMW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Samuel C. Silverstein et al.

U.S. Serial No.: Not Yet Known

Filed : Herewith

For : A NOVEL METHOD FOR USING PHAGOCYTIC PARTICLES AND ATP RECEPTORS TO DELIVER ANTIGENS TO MHC CLASS I RECEPTORS TO INDUCE IMMUNITY AGAINST MICROBIAL PATHOGENS OR TUMORS OR TO SUPPRESS IMMUNITY

1185 Avenue of the Americas
New York, New York 10036
September 8, 2000

Assistant Commissioner for Patents
Washington, D.C. 20231

Box: Patent Application

EXPRESS MAIL CERTIFICATE OF MAILING
FOR ABOVE-IDENTIFIED APPLICATION

"Express Mail" mailing label number: EK 166 980 907 US
Date of Deposit: September 8, 2000
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Printed Name: [illegible]

Respectfully submitted,

John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

Dkt. 60467/JPW/EMW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Samuel C. Silverstein et al.

U.S. Serial No.: Not Yet Known

Filed : Herewith

For : A NOVEL METHOD FOR USING PHAGOCYTIC PARTICLES AND ATP RECEPTORS TO DELIVER ANTIGENS TO MHC CLASS I RECEPTORS TO INDUCE IMMUNITY AGAINST MICROBIAL PATHOGENS OR TUMORS OR TO SUPPRESS IMMUNITY

1185 Avenue of the Americas
New York, New York 10036
September 8, 2000

Assistant Commissioner for Patents
Washington, D.C. 20231

Box: Patent Application

PRELIMINARY AMENDMENT

Please amend the above-identified application as follows:

In the claims:

Please cancel claims 33-132 and without prejudice to applicant's right to pursue the subject matter of these claims in a future continuation or divisional application.

REMARKS

Applicants have hereinabove canceled claims 33-132 without prejudice to applicants' right to pursue the subject matter of these claims in a continuation or divisional application at a later date. Accordingly, upon entry of the amendment claims 1-32 will be pending and under examination. Accordingly, applicants respectfully request entry of the Amendment.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee is deemed necessary in connection with the filing of this Preliminary Amendment. However, if any fee is required authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,

John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

Application for United States Letters Patent

To all whom it may concern:

Be it known that we, Samuel C. Silverstein, John D. Loike and Francesco DiVirgilio

have invented certain new and useful improvements in

A NOVEL METHOD FOR USING PHAGOCYTIC PARTICLES AND ATP RECEPTORS TO DELIVER ANTIGENS TO MHC CLASS I RECEPTORS TO INDUCE IMMUNITY AGAINST MICROBIAL PATHOGENS OR TUMORS OR TO SUPPRESS IMMUNITY

of which the following is a full, clear and exact description.

60467/JPW/EMW

A NOVEL METHOD FOR USING PHAGOCYTIC PARTICLES AND ATP RECEPTORS TO DELIVER ANTIGENS TO MHC CLASS I RECEPTORS TO INDUCE IMMUNITY AGAINST MICROBIAL PATHOGENS OR TUMORS OR TO SUPPRESS IMMUNITY

Preliminary work for the invention disclosed was herein made in the course of work under NIH Grant No. AI 20516. Accordingly, the U.S. Government has certain rights in this invention.

Throughout this application, various references are referred to within parentheses. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. Full bibliographic citation for these references may be found at the end of this application, preceding the claims.

BACKGROUND OF THE INVENTION

To initiate an adaptive immune response, antigen presenting cells (APCs) must process "foreign" proteins into peptides. These peptides associate with MHC proteins which transport these peptides to the APCs' plasma membrane where they are recognized in the context of MHC proteins by helper and cytotoxic T-cell precursors. Helper T-lymphocyte precursors recognize peptide in association with Class II MHC proteins while cytotoxic T-lymphocyte (CTL) precursors recognize peptide

in association with Class I MHC proteins.

The major types of APC's (mononuclear phagocytes and dendritic cells) express plasma membrane receptors for ATP^{4-} (1,2,3). These receptors are called $P2X_7$ receptors. Binding of ATP^{4-} to $P2X_7$ receptors opens a "pore" in the plasma membranes of macrophages (4), and of dendritic cells (3,5) that allows molecules of up to ~900 daltons M.W. into the cytoplasm of these cells without killing the cells. The ATP^{4-}-activated pore of macrophages was first identified by applicants. The $P2X_7$ receptor is formed by the association of multiple protein subunits each 595 aa long.

At neutral pH and in the presence of physiological salts most of the ATP in extracellular fluids is complexed with divalent cations, primarily Mg^{2+} and Ca^{2+}. Under these conditions, the equilibrium between $MgATP^{2-}/CaATP^{2-}$ and ATP^{4-} strongly favors $MgATP^{2-}/CaATP^{2-}$. Consequently, $[MgATP^{2-}/CaATP^{2-}]$ in excess of 3 mM are required to achieve an $[ATP^{4-}]$ of >130 μM, the $[ATP^{4-}]$ needed to induce pore formation by $P2X_7$ receptors (4). [ATP]>3mM are rarely if ever found in extracellular fluids under physiological conditions. However, apoptotic cells contain >5 mM ATP (6).

Scavenger receptors present on the plasma membranes of APCs promote the phagocytosis of apoptotic cells. Following their ingestion, apoptotic cells are sequestered and lysed within phagolysosomes of these APCs. This releases both ATP and various peptides into

the vacuole of the the APCs' phago-lysosome. It is hypnothesized that the ATP released from apoptotic cells into phagolysosomes of APCs opens $P2X_7$ receptors. This provides a pathway by which potentially immunogenic peptides from "foreign" apoptotic cells, and potentially "toleragenic" peptides from self apoptotic cells, enter the cytoplasm of APCs. These peptides then can be carried by TAP proteins into the endoplasmic reticulum where they associate with Class I MHC proteins. APCs and especially immature dendritic cells (1), recycle Class II MHC molecules from their phago-lysosomes to the plasma membrane. Thus peptide antigens released into phago-lysosomes are efficiently presented in association with Class II MHC proteins.

Antigen presenting cells (APCs) whose Class I and Class II MHC molecules contain antigen peptides elicit cytotoxic and helper T-lymphocytes. In some instances, these cytotoxic and helper lymphocytes cause tumor regression. Devised herein is a novel method for delivery of immunogenic peptides to macrophages and dendritic cells for presentation by Class I and Class II MHC proteins. The method uses as a delivery vehicle IgG-opsonized resealed red blood cell ghosts (rRBCg) containing immunogenic peptides for delivery to Class II MHC proteins, and IgG-opsonized-rRBCg containing immunogenic peptides and ATP for delivery to Class I MHC proteins. In the latter instance, the method makes use of ATP^{4-}-activated receptors (which may be $P2X_7$ or other ATP receptors) present in phagolysosomal vesicles to deliver immunogenic peptides to the cytoplasmic matrix of

APCs (i.e., dendritic cells and macrophages).

Human red blood cell ghosts or other particles that can be filled with antigens (e.g., liposomes) and coated with ligands (IgG, oxidized lipids, sugars, polyanions), for receptors on antigen presenting cells (e.g., dendritic cells, Langerhans cells, monocytes, macrophages), are used as vehicles to encapsulate antigens (e.g., peptides, carbohydrates lipids, glycoproteins, glycolipids, lipoproteins), and adenosine triphosphate (ATP) or other ligands for ATP receptors (e.g. P2X7 and other ATP receptors)]. The antigens may be an antigen derived from, and/or induce immune responses that affect microbial pathogens, tumor cells, and/or immuno-regulatory pathways. Ligands on the particle will promote ingestion of the particle by antigen presenting cells. Enzymes released into particle-containing phagosomes of antigen presenting cells will lyse the particle, releasing ATP and/or other substances that activate ATP receptors (such as P2X7 receptors, but not limited to these receptors) into these phagosomes. Activation of the receptors will create "pores" in the phagosomes' membranes through which antigens (e.g., antigenic peptides, carbohydrates, lipids) can enter the cytoplasm for processing and presentation to T-cells in association with conventional Class I MHC molecules, or other antigen presenting receptors.

The invention disclosed herein is useful as a vaccine, as a method for delivery of antigens to the cytoplasmic matrix of antigen presenting cells to induce immunity, to

activate cytotoxic effects against tumor cells, and/or to suppress immunity/induce tolerance. The delivery system may also be used to deliver Th1 stimulatory cytokines (e.g., Il-12, interfereon gamma) along with the antigen. The invention provided herein is a simple delivery system for purified antigens or crude cell extracts directly into the cytoplasmic matrix of antigen presenting cells for presentation by class I or II MHC and provides the advantage of not requiring isolation of host antigen presenting cells.

SUMMARY OF THE INVENTION

This invention provides a method of delivering an antigen to an Class I MHC receptor to induce immunity against the antigen in a subject having a disease which comprises: a) filling particles with the antigen and ATP resulting in an antigen- and ATP-filled particles (Ag/ATP-filled particles); b) coating the Ag/ATP-filled particles of step (a) with a ligand for an antigen presenting cell resulting in a ligand-coated Ag/ATP-filled particles; c) incubating the ligand-coated Ag/ATP-filled particles of step (b) with isolated ligand-binding antigen presenting cells (APCs) under conditions permitting the ligand-binding APCs to bind to the ligand-coated Ag/ATP-filled particles and APC phagolysosomes to ingest the ligand-coated Ag/ATP-filled particles to facilitate transfer of the ingested antigen from the phagolysosomes into cytoplasm such that the antigen is delivered to a Class I MHC receptor and is expressed on the surface of the APCs (Ag-APCs); and d) administering the antigen presenting cells (APCs) of step (c) to a subject having the disease so as induce Class I MHC presentation and elicit cytotoxic T-lymphocytes against the antigen, thereby inducing immunity against the antigen.

This invention provides a method of delivering an antigen to an Class I MHC receptor to induce immunity against the antigen in a subject having a disease which comprises: a) filling particles with the antigen and ATP resulting in an antigen- and ATP-filled particles (Ag/ATP-filled particles); b) coating the Ag/ATP-filled particles of

step (a) with a ligand for an antigen presenting cell resulting in a ligand-coated Ag/ATP-filled particles; c) incubating the ligand-coated Ag/ATP-filled particles of step (b) with isolated ligand-binding antigen presenting cells (APCs) under conditions permitting the ligand-binding APCs to bind to the ligand-coated Ag/ATP-filled particles and APC phagolysosomes to ingest the ligand-coated Ag/ATP-filled particles to facilitate transfer of the ingested antigen from the phagolysosomes into cytoplasm such that the antigen is delivered to a Class I MHC receptor and is expressed on the surface of the APCs (Ag-APCs); d) incubating the Ag-APCs of step (c) with lymphocytes previously removed from the subject having the disease; and e) administering the incubated lymphocytes of step (d) to the subject so to induce immunity against the antigen in the subject.

This invention provides a method of delivering an antigen to an Class II MHC receptor to induce immunity against the antigen in a subject having a disease which comprises: a) filling particles with the antigen and ATP resulting in an antigen- and ATP-filled particles (Ag/ATP-filled particles); b) coating the Ag/ATP-filled particles of step (a) with a ligand for an antigen presenting cell resulting in a ligand-coated Ag/ATP-filled particles; c) incubating the ligand-coated Ag/ATP-filled particles of step (b) with isolated ligand-binding antigen presenting cells (APCs) under conditions permitting the ligand-binding APCs to bind to the ligand-coated Ag/ATP-filled particles and APC phagolysosomes to ingest the ligand-coated Ag/ATP-filled particles to

facilitate transfer of the ingested antigen from the phagolysosomes into cytoplasm such that the antigen is delivered to a Class II MHC receptor and is expressed on the surface of the APCs (Ag-APCs); and d) administering the antigen presenting cells (APCs) of step (c) to a subject having the disease so as induce Class II MHC presentation and elicit helper T-lymphocytes against the antigen, thereby inducing immunity against the antigen.

This invention provides a method of delivering an antigen to an Class II MHC receptor to induce immunity against the antigen in a subject having a disease which comprises: a) filling particles with the antigen and ATP resulting in an antigen- and ATP-filled particles (Ag/ATP-filled particles); b) coating the Ag/ATP-filled particles of step (a) with a ligand for an antigen presenting cell resulting in a ligand-coated Ag/ATP-filled particles; c) incubating the ligand-coated Ag/ATP-filled particles of step (b) with isolated ligand-binding antigen presenting cells (APCs) under conditions permitting the ligand-binding APCs to bind to the ligand-coated Ag/ATP-filled particles and APC phagolysosomes to ingest the ligand-coated Ag/ATP-filled particles to facilitate transfer of the ingested antigen from the phagolysosomes into cytoplasm such that the antigen is delivered to a Class I MHC receptor and is expressed on the surface of the APCs (Ag-APCs); d) incubating the Ag-APCs of step (c) with lymphocytes previously removed from the subject having the disease; and e) administering the incubated lymphocytes of step (d) to the subject so as induce Class II MHC presentation and elicit helper T-

lymphocytes so to induce immunity against the antigen in the subject.

This invention provides a method of delivering an antigen to an Class II MHC receptor to supress immunity against the antigen in a subject having a disease which comprises: a) filling particles with the antigen and ATP resulting in an antigen- and ATP-filled particles (Ag/ATP-filled particles); b) coating the Ag/ATP-filled particles of step (a) with a ligand for an antigen presenting cell resulting in a ligand-coated Ag/ATP-filled particles; c) incubating the ligand-coated Ag/ATP-filled particles of step (b) with isolated ligand-binding antigen presenting cells (APCs) under conditions permitting the ligand-binding APCs to bind to the ligand-coated Ag/ATP-filled particles and APC phagolysosomes to ingest the ligand-coated Ag/ATP-filled particles to facilitate transfer of the ingested antigen from the phagolysosomes into cytoplasm such that the antigen is delivered to a Class II MHC receptor and is expressed on the surface of the APCs (Ag-APCs); d) incubating the Ag-APCs of step (c) with lymphocytes previously removed from the subject having the disease; and e) administering the incubated lymphocytes of step (d) to the subject so as induce Class II MHC presentation and elicit suppressor T-lymphocytes so to supress immunity against the antigen in the subject.

This invention provides a method of delivering an antigen to an Class I MHC receptor to supress immunity against the antigen in a subject having a disease which

comprises: a) filling particles with the antigen and ATP resulting in an antigen- and ATP-filled particles (Ag/ATP-filled particles); b) coating the Ag/ATP-filled particles of step (a) with a ligand for an antigen presenting cell resulting in a ligand-coated Ag/ATP-filled particles; c) incubating the ligand-coated Ag/ATP-filled particles of step (b) with isolated ligand-binding antigen presenting cells (APCs) under conditions permitting the ligand-binding APCs to bind to the ligand-coated Ag/ATP-filled particles and APC phagolysosomes to ingest the ligand-coated Ag/ATP-filled particles to facilitate transfer of the ingested antigen from the phagolysosomes into cytoplasm such that the antigen is delivered to a Class I MHC receptor and is expressed on the surface of the APCs (Ag-APCs); d) incubating the Ag-APCs of step (c) with lymphocytes previously removed from the subject having the disease; and e) administering the incubated lymphocytes of step (d) to the subject so as induce Class I MHC presentation and elicit suppressor T-lymphocytes so to supress immunity against the antigen in the subject.

This invention provides a method of delivering an antigen to an Class I MHC receptor to supress immunity against the antigen in a subject having a disease which comprises: a) filling particles with the antigen and ATP resulting in an antigen- and ATP-filled particles (Ag/ATP-filled particles); b) coating the Ag/ATP-filled particles of step (a) with a ligand for an antigen presenting cell resulting in a ligand-coated Ag/ATP-filled particles; c) incubating the ligand-coated Ag/ATP-

filled particles of step (b) with isolated ligand-binding antigen presenting cells (APCs) under conditions permitting the ligand-binding APCs to bind to the ligand-coated Ag/ATP-filled particles and APC phagolysosomes to ingest the ligand-coated Ag/ATP-filled particles to facilitate transfer of the ingested antigen from the phagolysosomes into cytoplasm such that the antigen is delivered to a Class I MHC receptor and is expressed on the surface of the APCs (Ag-APCs); and d) administering the antigen presenting cells (APCs) of step (c) to a subject having the disease so as induce Class I MHC presentation and elicit suppressor T-lymphocytes so to supress immunity against the antigen in the subject.

This invention provides a method of delivering an antigen to an Class II MHC receptor to supress immunity against the antigen in a subject having a disease which comprises: a) filling particles with the antigen and ATP resulting in an antigen- and ATP-filled particles (Ag/ATP-filled particles); b) coating the Ag/ATP-filled particles of step (a) with a ligand for an antigen presenting cell resulting in a ligand-coated Ag/ATP-filled particles; c) incubating the ligand-coated Ag/ATP-filled particles of step (b) with isolated ligand-binding antigen presenting cells (APCs) under conditions permitting the ligand-binding APCs to bind to the ligand-coated Ag/ATP-filled particles and APC phagolysosomes to ingest the ligand-coated Ag/ATP-filled particles to facilitate transfer of the ingested antigen from the phagolysosomes into cytoplasm such that the antigen is delivered to a Class II MHC receptor and is expressed on

the surface of the APCs (Ag-APCs); and d) administering the antigen presenting cells (APCs) of step (c) to a subject having the disease so as induce Class II MHC presentation and elicit suppressor T-lymphocytes so to supress immunity against the antigen in the subject.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1: **Mouse Fetal Microglial Cells.** Mouse fetal microglial cells were incubated with IgG opsonized red blood cell resealed ghosts (containing ATP and lucifer yellow). At the indicated times, the cells were observed under fluorescence microscopy. At 60 mins and 4 hours, the microglial cells ingested the particles and the dye is still contained within red blood cell ghosts. However, within 24 hrs, the dye has left the phagolysosome and now appears throughout the cytoplasm of the cells. (LY=lucifer yellow)

Figure 2: **Human Monocyte Derived Dendritic Cells.** At 24 hours, the dendritic cells that have ingested the IgG opsonized red blood cell resealed ghosts (containing ATP and lucifer yellow) now express the dye throughout the cytoplasm of the cell.

Figure 3: **B6 Bone Marrow Derived Dendritic Cells 3 hr Fl-Ova-E(IgG).** Mouse Bone marrow derived dendritic cells were incubated for about 4 hours with IgG opsonized red blood cell resealed ghosts (containing ATP and fluorochrome conjugated ovalbumin peptide [fl-ova]). In many of the cells, the fluorochrome dye is observed to be localized throughout the cytoplasm rather than in phagolysosomes.

Figures 4A-4B: **Determination of permeabilization of molecules from phago-lysosomes to the cytoplasmic matrix.** IgG-coated resealed sheep red blood cell ghosts (IgG-rRBCg) containing the fluorescent dye Lucifer Yellow (LY) with or without ATP were prepared and these ghosts were incubated with monolayers of J774 macrophage-like cells at 37°. In IgG-rRBCg lacking ATP, apyrase was loaded into the RBCg to hydrolyze endogenous ATP. After 60 mins., monolayers were briefly exposed to distilled water to lyse undigested IgG-rRBCg+LY+ATP or IgG-rRBCg+LY and examined by phase and fluorescence microscopy. Fig. 4A. About 50% of the J774 cells that had ingested IgG-rRBCg+LY+ATP contained LY in their cytoplasmic and nuclear matrices. Fig. 4B. No LY was detected in the cytoplasmic or nuclear matrices of J774 cells that had ingested IgG-rRBCg+LY at any time from 0.5 to 48 hrs.

DETAILED DESCRIPTION OF THE INVENTION

This invention provides a method of delivering an antigen to an Class I MHC receptor to induce immunity against the antigen in a subject having a disease which comprises: a) filling particles with the antigen and ATP resulting in an antigen- and ATP-filled particles (Ag/ATP-filled particles); b) coating the Ag/ATP-filled particles of step (a) with a ligand for an antigen presenting cell resulting in a ligand-coated Ag/ATP-filled particles; c) incubating the ligand-coated Ag/ATP-filled particles of step (b) with isolated ligand-binding antigen presenting cells (APCs) under conditions permitting the ligand-binding APCs to bind to the ligand-coated Ag/ATP-filled particles and APC phagolysosomes to ingest the ligand-coated Ag/ATP-filled particles to facilitate transfer of the ingested antigen from the phagolysosomes into cytoplasm such that the antigen is delivered to a Class I MHC receptor and is expressed on the surface of the APCs (Ag-APCs); and d) administering the antigen presenting cells (APCs) of step (c) to a subject having the disease so as induce Class I MHC presentation and elicit cytotoxic T-lymphocytes against the antigen, thereby inducing immunity against the antigen.

In an embodiment of the above-described method of delivering an antigen to an Class I MHC receptor to induce immunity against the antigen in a subject having a disease, the particle is a type O red blood cell ghost. In another embodiment of the method the particle is a liposome. In an embodiment the ligand is selected from

the group consisting of an immunoglobulin (IgG), complement component C3b, complement component C3bi, maleic anhydride, an oxidized lipid, a sugar, and a polyanion. In a further embodiment the antigen presenting cell is selected from the group consisting of a dendritic cell, a Langerhans cell, a monocyte, a mononuclear phagocyte, a macrophage, a Kupfer cell, a microglial cell, an osteoclast, and a bone marrow-derived leukocyte. In an embodiment the antigen is a purified antigen. In preferred embodiments the antigen is a cancer cell antigen, a bacterial antigen or a viral antigen. In an embodiment the antigen is a crude cell extract. In additional preferred embodiments the antigen is a cancer cell antigen, a bacterial antigen or a viral antigen. In an embodiment the antigen is selected from the group consisting of a peptide, a carbohydrate, a lipid, a glycoprotein, a glycolipid and a lipoprotein. In another embodiment of the above-described methods, the method further comprises delivering at least one stimulatory cytokine with the antigen to the cytoplasmic matrix of an antigen presenting cell which comprises in step (a) filling the particle with the stimulatory cytokine. In an embodiment the cytokine is IL-12, G-CSF, IL-4, GM-CSF or interferon gamma. In preferred embodiments the immunity induced is against a bacterial or viral antigen. In still further preferred embodiments the immunity induced is against a cancerous tumor. In preferred embodiments the disease is a bacterial infection or a viral infection. In additional preferred embodiments the disease is cancer.

This invention provides a method of delivering an antigen to an Class I MHC receptor to induce immunity against the antigen in a subject having a disease which comprises: a) filling particles with the antigen and ATP resulting in an antigen- and ATP-filled particles (Ag/ATP-filled particles); b) coating the Ag/ATP-filled particles of step (a) with a ligand for an antigen presenting cell resulting in a ligand-coated Ag/ATP-filled particles; c) incubating the ligand-coated Ag/ATP-filled particles of step (b) with isolated ligand-binding antigen presenting cells (APCs) under conditions permitting the ligand-binding APCs to bind to the ligand-coated Ag/ATP-filled particles and APC phagolysosomes to ingest the ligand-coated Ag/ATP-filled particles to facilitate transfer of the ingested antigen from the phagolysosomes into cytoplasm such that the antigen is delivered to a Class I MHC receptor and is expressed on the surface of the APCs (Ag-APCs); d) incubating the Ag-APCs of step (c) with lymphocytes previously removed from the subject having the disease; and e) administering the incubated lymphocytes of step (d) to the subject so to induce immunity against the antigen in the subject.

In an embodiment of the above-described method of delivering an antigen to an Class I MHC receptor to induce immunity against the antigen in a subject having a disease, the particle is a type O red blood cell ghost. In an embodiment the particle is a liposome. In another embodiment the ligand is selected from the group consisting of an immunoglobulin (IgG), complement component C3b, complement component C3bi, maleic

anhydride, an oxidized lipid, a sugar, and a polyanion. In a further embodiment the antigen presenting cell is selected from the group consisting of a dendritic cell, a Langerhans cell, a monocyte, a mononuclear phagocyte, a macrophage, a Kupfer cell, a microglial cell, an osteoclast, and a bone marrow-derived leukocyte. In an embodiment the antigen is a purified antigen. In a preferred embodiment the purified antigen is a cancer cell antigen, a bacterial antigen or a viral antigen. In an embodiment the antigen is a crude cell extract. In another preferred embodiment the crude cell extract antigen is a cancer cell antigen, a bacterial antigen or a viral antigen. In an embodiment the antigen is selected from the group consisting of a peptide, a carbohydrate, a lipid, a glycoprotein, a glycolipid and a lipoprotein. In another embodiment of the above-described method the method further comprises delivering at least one stimulatory cytokine with the antigen to the cytoplasmic matrix of an antigen presenting cell which comprises in step (a) filling the particle with the stimulatory cytokine. In an embodiment the cytokine is IL-12, G-CSF, IL-4, GM-CSF or interferon gamma. In a preferred embodiment the immunity induced is against a bacterial or viral antigen. In another preferred embodiment the immunity induced is against a cancerous tumor. In a further preferred embodiment the disease is a bacterial infection or a viral infection. In a still further preferred embodiment the disease is cancer.

This invention provides a method of delivering an antigen to an Class II MHC receptor to induce immunity against

the antigen in a subject having a disease which comprises: a) filling particles with the antigen and ATP resulting in an antigen- and ATP-filled particles (Ag/ATP-filled particles); b) coating the Ag/ATP-filled particles of step (a) with a ligand for an antigen presenting cell resulting in a ligand-coated Ag/ATP-filled particles; c) incubating the ligand-coated Ag/ATP-filled particles of step (b) with isolated ligand-binding antigen presenting cells (APCs) under conditions permitting the ligand-binding APCs to bind to the ligand-coated Ag/ATP-filled particles and APC phagolysosomes to ingest the ligand-coated Ag/ATP-filled particles to facilitate transfer of the ingested antigen from the phagolysosomes into cytoplasm such that the antigen is delivered to a Class II MHC receptor and is expressed on the surface of the APCs (Ag-APCs); and d) administering the antigen presenting cells (APCs) of step (c) to a subject having the disease so as induce Class II MHC presentation and elicit helper T-lymphocytes against the antigen, thereby inducing immunity against the antigen.

In an embodiment of the above-described method of delivering an antigen to an Class II MHC receptor to induce immunity against the antigen in a subject having a disease the particle is a type O red blood cell ghost. In an embodiment the particle is a liposome. In another embodiment the ligand is selected from the group consisting of an immunoglobulin (IgG), complement component C3b, complement component C3bi, maleic anhydride, an oxidized lipid, a sugar, and a polyanion. In a further embodiment the antigen presenting cell is

selected from the group consisting of a dendritic cell, a Langerhans cell, a monocyte, a mononuclear phagocyte, a macrophage, a Kupfer cell, a microglial cell, an osteoclast, and a bone marrow-derived leukocyte. In an embodiment the antigen is a purified antigen. In a preferred embodiment the purified antigen is a cancer cell antigen, a bacterial antigen or a viral antigen. In an embodiment the antigen is a crude cell extract. In an embodiment the crude cell extract antigen is a cancer cell antigen, a bacterial antigen or a viral antigen. In an embodiment the antigen is selected from the group consisting of a peptide, a carbohydrate, a lipid, a glycoprotein, a glycolipid and a lipoprotein. In an embodiment of the above-described methods, the method further comprising delivering at least one stimulatory cytokine with the antigen to the cytoplasmic matrix of an antigen presenting cell which comprises in step (a) filling the particle with the stimulatory cytokine. In an embodiment the cytokine is IL-12, G-CSF, IL-4, GM-CSF or interferon gamma. In a preferred eembodiment the immunity induced is against a bacterial or viral antigen. In another preferred eembodiment the immunity induced is against a cancerous tumor. In other preferred embodiments the disease is a bacterial infection or a viral infection. In further preferred eembodiment the disease is cancer.

This invention provides a method of delivering an antigen to an Class II MHC receptor to induce immunity against the antigen in a subject having a disease which comprises: a) filling particles with the antigen and ATP

resulting in an antigen- and ATP-filled particles (Ag/ATP-filled particles); b) coating the Ag/ATP-filled particles of step (a) with a ligand for an antigen presenting cell resulting in a ligand-coated Ag/ATP-filled particles; c) incubating the ligand-coated Ag/ATP-filled particles of step (b) with isolated ligand-binding antigen presenting cells (APCs) under conditions permitting the ligand-binding APCs to bind to the ligand-coated Ag/ATP-filled particles and APC phagolysosomes to ingest the ligand-coated Ag/ATP-filled particles to facilitate transfer of the ingested antigen from the phagolysosomes into cytoplasm such that the antigen is delivered to a Class I MHC receptor and is expressed on the surface of the APCs (Ag-APCs); d) incubating the Ag-APCs of step (c) with lymphocytes previously removed from the subject having the disease; and e) administering the incubated lymphocytes of step (d) to the subject so as induce Class II MHC presentation and elicit helper T-lymphocytes so to induce immunity against the antigen in the subject.

In an embodiment of the above-described method of delivering an antigen to an Class II MHC receptor to induce immunity against the antigen in a subject having a disease the particle is a type O red blood cell ghost. In an embodiment the particle is a liposome. In another embodiment the ligand is selected from the group consisting of an immunoglobulin (IgG), complement component C3b, complement component C3bi, maleic anhydride, an oxidized lipid, a sugar, and a polyanion. In a further embodiment the antigen presenting cell is

selected from the group consisting of a dendritic cell, a Langerhans cell, a monocyte, a mononuclear phagocyte, a macrophage, a Kupfer cell, a microglial cell, an osteoclast, and a bone marrow-derived leukocyte. In an embodiment the antigen is a purified antigen. In a preferred embodiment the purified antigen is a cancer cell antigen, a bacterial antigen or a viral antigen. In another embodiment the antigen is a crude cell extract. In a preferred embodiment the crude cell extract antigen is antigen is a cancer cell antigen, a bacterial antigen or a viral antigen. In an embodiment the antigen is selected from the group consisting of a peptide, a carbohydrate, a lipid, a glycoprotein, a glycolipid and a lipoprotein. In another embodiment of the above-described methods, the method further comprises delivering at least one stimulatory cytokine with the antigen to the cytoplasmic matrix of an antigen presenting cell which comprises in step (a) filling the particle with the stimulatory cytokine. In an embodiment the cytokine is IL-12, G-CSF, IL-4, GM-CSF or interferon gamma. In a preferred embodiment the immunity induced is against a bacterial or viral antigen. In another preferred embodiment the immunity induced is against a cancerous tumor. In further preferred embodiment the disease is a bacterial infection or a viral infection. In another preferred embodiment the disease is cancer.

This invention provides a method of delivering an antigen to an Class II MHC receptor to supress immunity against the antigen in a subject having a disease which comprises: a) filling particles with the antigen and ATP

resulting in an antigen- and ATP-filled particles (Ag/ATP-filled particles); b) coating the Ag/ATP-filled particles of step (a) with a ligand for an antigen presenting cell resulting in a ligand-coated Ag/ATP-filled particles; c) incubating the ligand-coated Ag/ATP-filled particles of step (b) with isolated ligand-binding antigen presenting cells (APCs) under conditions permitting the ligand-binding APCs to bind to the ligand-coated Ag/ATP-filled particles and APC phagolysosomes to ingest the ligand-coated Ag/ATP-filled particles to facilitate transfer of the ingested antigen from the phagolysosomes into cytoplasm such that the antigen is delivered to a Class II MHC receptor and is expressed on the surface of the APCs (Ag-APCs); d) incubating the Ag-APCs of step (c) with lymphocytes previously removed from the subject having the disease; and e) administering the incubated lymphocytes of step (d) to the subject so as induce Class II MHC presentation and elicit suppressor T-lymphocytes so to supress immunity against the antigen in the subject.

In an embodiment of the above-described method of delivering an antigen to an Class II MHC receptor to supress immunity against the antigen in a subject having a disease the particle is a type O red blood cell ghost. In an embodiment the particle is a liposome. In another embodiment the ligand is selected from the group consisting of an immunoglobulin (IgG), complement component C3b, complement component C3bi, maleic anhydride, an oxidized lipid, a sugar, and a polyanion. In a further embodiment the antigen presenting cell is

selected from the group consisting of a dendritic cell, a Langerhans cell, a monocyte, a mononuclear phagocyte, a macrophage, a Kupfer cell, a microglial cell, an osteoclast, and a bone marrow-derived leukocyte. In an embodiment the antigen is a purified antigen. In a preferred embodiment of the purified antigen, the antigen is an antigen of a transplant organ. In an embodiment the transplant organ antigen is allogeneic antigen, a syngeneic antigen, or a xenogenic antigen. In another embodiment the antigen is a crude cell extract. In a preferred embodiment of the crude cell extract antigen the antigen is an antigen of a transplant organ. In an embodiment the transplant organ antigen is allogeneic antigen, a syngeneic antigen, or a xenogenic antigen. In another embodiment the antigen is selected from the group consisting of a peptide, a carbohydrate, a lipid, a glycoprotein, a glycolipid and a lipoprotein. In another embodiment of the above-described methods, the method further comprises delivering at least one stimulatory cytokine with the antigen to the cytoplasmic matrix of an antigen presenting cell which comprises in step (a) filling the particle with the stimulatory cytokine. In an embodiment the cytokine is IL-12, G-CSF, IL-4, GM-CSF or interferon gamma. In a preferred embodiment the immunity suppressed is immunity against a transplanted organ or tissue. In another preferred embodiment the immunity suppressed is immunity against organs of the subject. In still another preferred embodiment the disease is an autoimmune disease or rejection of a transplanted organ or tissue.

This invention provides a method of delivering an antigen to an Class I MHC receptor to supress immunity against the antigen in a subject having a disease which comprises: a) filling particles with the antigen and ATP resulting in an antigen- and ATP-filled particles (Ag/ATP-filled particles); b) coating the Ag/ATP-filled particles of step (a) with a ligand for an antigen presenting cell resulting in a ligand-coated Ag/ATP-filled particles; c) incubating the ligand-coated Ag/ATP-filled particles of step (b) with isolated ligand-binding antigen presenting cells (APCs) under conditions permitting the ligand-binding APCs to bind to the ligand-coated Ag/ATP-filled particles and APC phagolysosomes to ingest the ligand-coated Ag/ATP-filled particles to facilitate transfer of the ingested antigen from the phagolysosomes into cytoplasm such that the antigen is delivered to a Class I MHC receptor and is expressed on the surface of the APCs (Ag-APCs); d) incubating the Ag-APCs of step (c) with lymphocytes previously removed from the subject having the disease; and e) administering the incubated lymphocytes of step (d) to the subject so as induce Class I MHC presentation and elicit suppressor T-lymphocytes so to supress immunity against the antigen in the subject.

In an embodiment of the above-described method of delivering an antigen to an Class I MHC receptor to supress immunity against the antigen in a subject having a disease the particle is a type O red blood cell ghost. In another embodiment the particle is a liposome. In a further embodiment the ligand is selected from the group

consisting of an immunoglobulin (IgG), complement component C3b, complement component C3bi, maleic anhydride, an oxidized lipid, a sugar, and a polyanion. In another embodiment the antigen presenting cell is selected from the group consisting of a dendritic cell, a Langerhans cell, a monocyte, a mononuclear phagocyte, a macrophage, a Kupfer cell, a microglial cell, an osteoclast, and a bone marrow-derived leukocyte. In an embodiment the antigen is a purified antigen. In a preferred embodiment of the purified antigen, the antigen is an antigen of a transplant organ. In an embodiment the transplant organ antigen is allogeneic antigen, a syngeneic antigen, or a xenogenic antigen. In another embodiment the antigen is a purified antigen the antigen is a crude cell extract. In a preferred embodiment of the crude cell extract antigen, the antigen is an antigen of a transplant organ. In an embodiment the transplant organ antigen is allogeneic antigen, a syngeneic antigen, or a xenogenic antigen. In another embodiment the antigen is selected from the group consisting of a peptide, a carbohydrate, a lipid, a glycoprotein, a glycolipid and a lipoprotein. In an embodiment of the above-described methods, the method further comprises delivering at least one stimulatory cytokine with the antigen to the cytoplasmic matrix of an antigen presenting cell which comprises in step (a) filling the particle with the stimulatory cytokine. In an embodiment the cytokine is IL-12, G-CSF, IL-4, GM-CSF or interferon gamma. In a preferred embodiment the immunity suppressed is immunity against a transplanted organ or tissue. In other preferred embodiments the immunity suppressed is immunity

against organs of the subject. In additional preferred embodiments the disease is an autoimmune disease or rejection of a transplanted organ or tissue.

This invention provides a method of delivering an antigen to an Class I MHC receptor to supress immunity against the antigen in a subject having a disease which comprises: a) filling particles with the antigen and ATP resulting in an antigen- and ATP-filled particles (Ag/ATP-filled particles); b) coating the Ag/ATP-filled particles of step (a) with a ligand for an antigen presenting cell resulting in a ligand-coated Ag/ATP-filled particles; c) incubating the ligand-coated Ag/ATP-filled particles of step (b) with isolated ligand-binding antigen presenting cells (APCs) under conditions permitting the ligand-binding APCs to bind to the ligand-coated Ag/ATP-filled particles and APC phagolysosomes to ingest the ligand-coated Ag/ATP-filled particles to facilitate transfer of the ingested antigen from the phagolysosomes into cytoplasm such that the antigen is delivered to a Class I MHC receptor and is expressed on the surface of the APCs (Ag-APCs); and d) administering the antigen presenting cells (APCs) of step (c) to a subject having the disease so as induce Class I MHC presentation and elicit suppressor T-lymphocytes so to supress immunity against the antigen in the subject.

In an embodiment of the above-described method of delivering an antigen to an Class I MHC receptor to supress immunity against the antigen in a subject having a disease the particle is a type O red blood cell ghost.

In another embodiment the particle is a liposome. In a further embodiment the ligand is selected from the group consisting of an immunoglobulin (IgG), complement component C3b, complement component C3bi, maleic anhydride, an oxidized lipid, a sugar, and a polyanion. In yet another embodiment the antigen presenting cell is selected from the group consisting of a dendritic cell, a Langerhans cell, a monocyte, a mononuclear phagocyte, a macrophage, a Kupfer cell, a microglial cell, an osteoclast, and a bone marrow-derived leukocyte. In an embodiment the antigen is a purified antigen. In a preferred embodiment of the purified antigen the antigen is an antigen of a transplant organ. In an embodiment the transplant organ antigen is allogeneic antigen, a syngeneic antigen, or a xenogenic antigen. In another embodiment the antigen is a crude cell extract. In a preferred embodiment of the a crude cell extract the antigen is an antigen of a transplant organ. In an embodiment the transplant organ antigen is allogeneic antigen, a syngeneic antigen, or a xenogenic antigen. In another embodiment the antigen is selected from the group consisting of a peptide, a carbohydrate, a lipid, a glycoprotein, a glycolipid and a lipoprotein. In an embodiment of the above-described methods, the method further comprises delivering at least one stimulatory cytokine with the antigen to the cytoplasmic matrix of an antigen presenting cell which comprises in step (a) filling the particle with the stimulatory cytokine. In an embodiment the cytokine is IL-12, G-CSF, IL-4, GM-CSF or interferon gamma. In a preferred embodiment the immunity suppressed is immunity against a transplanted organ or

tissue. In another preferred embodiment the immunity suppressed is immunity against organs of the subject. In a still further preferred embodiment the disease is an autoimmune disease or rejection of a transplanted organ or tissue.

This invention provides a method of delivering an antigen to an Class II MHC receptor to supress immunity against the antigen in a subject having a disease which comprises: a) filling particles with the antigen and ATP resulting in an antigen- and ATP-filled particles (Ag/ATP-filled particles); b) coating the Ag/ATP-filled particles of step (a) with a ligand for an antigen presenting cell resulting in a ligand-coated Ag/ATP-filled particles; c) incubating the ligand-coated Ag/ATP-filled particles of step (b) with isolated ligand-binding antigen presenting cells (APCs) under conditions permitting the ligand-binding APCs to bind to the ligand-coated Ag/ATP-filled particles and APC phagolysosomes to ingest the ligand-coated Ag/ATP-filled particles to facilitate transfer of the ingested antigen from the phagolysosomes into cytoplasm such that the antigen is delivered to a Class II MHC receptor and is expressed on the surface of the APCs (Ag-APCs); and d) administering the antigen presenting cells (APCs) of step (c) to a subject having the disease so as induce Class II MHC presentation and elicit suppressor T-lymphocytes so to supress immunity against the antigen in the subject.

In the above-described method of delivering an antigen to an Class II MHC receptor to supress immunity against the

antigen in a subject having a disease the particle is a type O red blood cell ghost. In another embodiment of the method method the particle is a liposome. In a further embodiment the ligand is selected from the group consisting of an immunoglobulin (IgG), complement component C3b, complement component C3bi, maleic anhydride, an oxidized lipid, a sugar, and a polyanion. In another embodiment the antigen presenting cell is selected from the group consisting of a dendritic cell, a Langerhans cell, a monocyte, a mononuclear phagocyte, a macrophage, a Kupfer cell, a microglial cell, an osteoclast, and a bone marrow-derived leukocyte. In yet another embodiment the antigen is a purified antigen. In a preferred embodiment of the purified antigen, the antigen is an antigen of a transplant organ. In an embodiment the transplant organ antigen is allogeneic antigen, a syngeneic antigen, or a xenogenic antigen. In another embodiment the antigen is a crude cell extract. In a preferred embodiment of the crude cell extract antigen, the antigen is an antigen of a transplant organ. In an embodiment the transplant organ antigen is allogeneic antigen, a syngeneic antigen, or a xenogenic antigen. In a further embodiment the antigen is selected from the group consisting of a peptide, a carbohydrate, a lipid, a glycoprotein, a glycolipid and a lipoprotein. In an embodiment of the above-described methods, the method further comprises delivering at least one stimulatory cytokine with the antigen to the cytoplasmic matrix of an antigen presenting cell, step (a) comprises filling the particle with the stimulatory cytokine. In additional embodiments the cytokine is IL-12, G-CSF, IL-

4, GM-CSF or interferon gamma. In a preferred embodiment the immunity suppressed is immunity against a transplanted organ or tissue. In another preferred embodiment the immunity suppressed is immunity against organs of the subject. In further preferred embodiments the disease is an autoimmune disease or rejection of a transplanted organ or tissue.

This invention will be better understood from the Experimental Details which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims which follow thereafter.

EXPERIMENTAL DETAILS

First Series of Experiments

Methods and Materials

Preparation of Red Blood Cell ghosts loaded with either indicator dye, peptide (antigen) or protein.

Lyse either human or sheep red blood cells in hypotonic KCl buffer containing 5 mM ATP and either a) indicator dye such as lucifer yellow at 5 mg/ml, b) peptides such as fluorescence-labelled ovalbumin, c) proteins, or d) lysate of tumor cells at 4°C for 20 mins. The same procedure can be done without adding ATP to the red blood cells.

Reseal ghosts in hypertonic KCl buffer to achieve isotonicity at 37°C for 40 mins.

Wash cells several times in phosphate buffered saline.

Opsonize (using published techniques) the red cells with the appropriate ligand which could be a) immunoglobulin (IgG), b) complement component C3b, c) complement component C3bi, d) maleic anhydride or others.

Add these opsonized ATP/peptide red blood cell resealed ghosts to isolated human dendritic cells obtained from either blood, bone marrow, brain, liver, skin or lymph nodes. Let the dendritic cells ingest the opsonized

ATP/peptide red blood cell resealed ghosts for several (3-24) hours with the appropriate cytokine such as GCSF, IL4, GMCSF, gamma interferon. The peptide will then be transferred from the phagolysosomes to other cytoplasmic compartments and eventually will be expressed as MHC class I antigens on the surface of the dendritic cells.

Either a) co-incubate these dendritic cells with lymphocytes in vitro for 6 hrs and then reinject the lymphocytes into the patient or b) inject these dendritic cells directly into the patient.

These dendritic cells should then induce class I MHC presentation and elicit cytotoxic T cells against the desired antigen. For example this method may be effective in generating an immunological response against tumors or microbial agents.

Opsonization of the red blood cell ghosts with C3bi enhances the transfer of lucifer yellow to the ctyoplasm.

Shown herein is preparation of opsonized ATP/peptide red blood cell resealed ghosts containing either an indicator dye such as lucifer yellow (LY) or a peptide such as fluorescein-conjugated ovalbumin peptide (amino acids 257-264).

These opsonized ATP/peptide red blood cell resealed ghosts are now ingested by either mouse microglial cells (an antigen presenting macrophage like cell found in the brain) (Figure 1), human blood monocyte derived dendritic

cells (Figure 2) or bone derived mouse dendritic cells (Figure 3).

Within 24 hr, the indicator dye or indicator peptide is transfered from the phagolysosome to one or more different cytoplasmic compartments which allows the peptide to then be processed and presented to class I MHC.

It is shown herein that if a peptide such as ovalbumin is loaded into the IgG opsonized red blood cell resealed ghosts and then incubated with mouse bone derived dendritic cells - the dendritic cells will present class I MHC and induce cytotoxic CD8 lymphocytes as measured by the capacity of these lymphocytes to proliferate in response to co-incubation of the dendritic cells with CD8 lymphocytes. (Table 1)

Table 1: Mouse Bone marrow derived dendritic cells prepared as described in Figure 3 were incubated with the appropriate isogenic spleen derived CD8 lymphocytes for several hours and then the CTL response was assayed by radiolabeled thymidine incorporation into the lymphocytes indicating a proliferative response mediated via class I MHC.

Table 1. Class I antigen presentation via Ova peptide

Mouse bone derived dendritic cells treated with:	CTL Assay- ^{3}H-thymidine uptake (proliferation assay-cpm)*
Soluble Ova protein (10 mg/ml)	160,000
Soluble Ova peptide (100 ng/ml)	90,000
E(IgG) loaded with ATP and Ova peptide (100 ng/ml)	130,000
E(IgG) loaded with ATP and Ova peptide (10 ng/ml)	22,000
E(IgG) loaded with apyrase and Ova peptide (10 ng/ml)	23,000

* in the absence of added antigen or with RBC's: cpms were <500.

Second Series of Experiments

To determine whether $P2X_7$ receptors mediate permeabilization of molecules from phago-lysosomes to the cytoplasmic matrix, prepared were IgG-coated resealed sheep red blood cell ghosts (IgG-rRBCg) containing the fluorescent dye Lucifer Yellow (LY) with or without ATP, and these ghosts were incubated with monolayers of J774 macrophage-like cells at 37°C. In IgG-rRBCg lacking ATP, apyrase was loaded into the RBCg to hydrolyze endogenous ATP. After 60 minutes, monolayers were briefly exposed to distilled water to lyse uningested IgG-rRBCg+LY+ATP or IgG-rRBCg+LY and examined by phase and fluorescence microscopy. As expected, >90% of the macrophages ingested one or more IgG-rRBCg+LY+ATP or IgG-rRBCg+LY. These brightly fluorescent IgG-rRBCgs were contained in phago-lysosomes in the J774 cells' cytoplasm. About 50% of the J774 cells that had ingested IgG-rRBCg+LY+ATP contained LY in their cytoplasmic and nuclear matrices (see Figure 4A). The LY remained in the cytoplasmic and nuclear matrices of J774 cells that ingested IgGrRBCg+LY+ATP for 48 hours, the longest time point examined. In contrast, no LY was detected in the cytoplasmic or nuclear matrices of J774 cells that had ingested IgGrRBCg+LY at any time from 0.5 to 48 hours (Figure 4B). Similar results were obtained using thioglycollate elicited mouse peritoneal macrophages (data not shown). To confirm these results J774 cells which lack $P2X_7$ receptors (J774-$P2X_7$ null) were used. These cells were selected and characterized as described (7). About 60% of J774-$P2X_7$ null cells ingested

IgGrRBCg+LY+ATP but none of these cells exhibited LY in their cytoplasmic or nuclear matrices 0.5 to 48 hours later. All the LY remained within the phago-lysosomes (data not shown).

Previous studies confirmed that dyes such as fura 2, ~850 M.W. (8), and LY covalently linked to the alpha amino group of glycyl-glycine (M.W.~632) (Silverstein, unpublished observations), penetrate plasma membrane pores formed by ATP^{4-}-activated $P2X_7$ receptors of J774 cells. Thus, ATP-activated $P2X_7$ receptors are permeable to peptides. Since T-cell receptors recognize foreign peptides 9 to 10 amino acids in length in association with Class I MHC molecules and the average M.W. for a nona-peptide is ~900, there is every reason to believe that pores formed by $P2X_7$ receptors will be permeable to nona- and deca-peptides.

Experimental plan: 1. Whether murine macrophages and J774 cells present the β-galactosidase nona-peptide TPHPARIGL in a Class I MHC restricted fashion when they ingest IgGrRBCg+ATP.

Peritoneal macrophages from Balb/c mice, or J774 cells ($H\text{-}2L^d$), loaded with TPHPARIGL (residues 876-884 of *E. coli* β-galactosidase) are lysed by the $H\text{-}2L^d$ -restricted murine cytotoxic T-cell line 0805B (CTL0805B). CTL0805B cells, kindly provided by Dr. Michael Bevan, University of Washington. IgG-rRBCg will be loaded with TPHPARIGL plus LY, or TPHPARIGL plus LY plus 5 mM ATP (e.g., IgGrRBCg+TPHPARIGL+LY+ATP or IgGrRBCg+TPHPARIGL+LY),

washed to remove free peptide, and incubated at 37°C for 1 hour with monolayers of macrophages or of J774 cells. (Ghosts containing TPHPARIGL, LY and ATP will be used in the initial experiments to confirm that these ghosts are being ingested and that ATP in them activates $P2X_7$ receptors that allow LY into the cytoplasmic and nuclear matrices. Furthermore, as described above endogenous ATP from IgGrRBCg+TPHPARIGL+LY will be hydrolyzed by loading these ghosts with apyrase.) Uningested IgGrRBCg will be removed by lysis as described above, the peritoneal macrophages or J774 cells will be further incubated at 37°C for varying time periods to allow processing of the TPHPARIGL. The macrophages or J774 cells then will be labeled with ^{51}Cr and incubated with various ratios of CTL0805B cells (e.g., 10-50 CTL0805B cells per target cell) for 4 hours at 37°C, at which time the medium from these cultures will be collected, sedimented to remove detached but unlysed cells, and assayed for ^{51}Cr release as a measure of cytotoxicity, as described (8). Positive controls should show that CTL0805B will lyse macrophages, wild type J774 cells, or J774-$P2X_7$ null cells that were pre-loaded incubated with high concentrations of TPHPARIGL peptide prior to incubating them with CTL0805B. CTL0805B should not lyse the following cells: 1. Macrophages or J774 cells treated with cytochalasin D to prevent ingestion of the IgGrRBCg+TPHPARIGL+ATP or of the IgGrRBCg+TPHPARIGL. 2. J774-$P2X_7$ null cells incubated with IgGrRBCg+TPHPARIGL+ATP or IgGrRBCg+TPHPARIGL. 3. Macrophages or J774 cells treated with Brefeldin A to prevent transport of TPHPARGL-loaded Class I MHC proteins from the endoplasmic reticulum to the surface. 4.

Macrophages or J774 cells incubated with IgGrRBCg+ATP and a scrambled peptide to which CTL0805B cells do not react. Anticipated results: CTL0805B will only kill syngeneic macrophages or wild type J774 cells that have processed IgGrRBCg+TPHPARIGL+ATP.

Experimental plan: 2. Whether IgCrRBCg containing TPHPARIGL and ATP, but not IgGrRBCg containing - TPHPARIGL but lacking ATP, can be used to immunize naive mice to form CTL that lyse sygeneic macrophages or J774 cells loaded with the peptide.

Balb/c mice will be immunized weekly for 3-6 weeks intra-peritoneally, or subcutaneously in the neck or hind footpad with rRBCg or IgGrRBCg containing TPHPARIGL with or without ATP. As a control, similar numbers of mice will be immunized with J774 cells incubated in TPHPARIGL-containing buffer to load Class I MHC proteins with this peptide as described (8). For mice immunized subcutaneously, T-lymphocytes will be obtained from regional lymph nodes and spleen. For mice immunized intra-peritoneally T-lymphocytes will be obtained from spleen. Spleen and lymph node cells from immunized mice will be tested for induction of CTL against TPHPARIGL-pulsed Balb/c macrophages (syngeneic), TPHPARIGL-pulsed C57B1/6 macrophages (allogeneic), or J774 cells, as in 1. above, and for helper T-lymphocyte activity using ^{3}H-thymidine incorporation or IL-2 production using X-irradiated lac-Z transfected Balb/c 3T3 cells (9). In a second series of experiments Balb/c dendritic cells or marcrophages will be allowed to ingest IgGrRBCg

containing TPHPARIGL with or without ATP. Uningested IgGrRBCg+TPHPARIGL will be lysed, and these APCs will be administered to Balb/c mice weekly for 3-6 weeks intra-peritoneally or subcutaneously. The mice then will be sacrificed and their spleen and regional lymph node cells tested for CTL activity against TPHPARIGL-pulsed J774 cells (as described in 8), and for helper T-lymphocytes using ^{3}H-thymidine incorporation or IL-2 production using X-irradiated lac-Z transfected Balb/c 3T3 cells as stimulators (9).

Anticipated results: rRBCg+TPHPARIGL+ATP, IgGrRBCg TPHPARIGEL+ATP, or macrophages or dendritic cells that ingested IgGrRBCg TPHPARIGEL+ATP will induce formation of CTLs while rRBCg+TPHPARIGEL, IgGrRBCg+TPHPARIGEL, or macrophages or dendtitic cells that ingested IgGrRBCg+TPHPARIGEL will not. In contrast, all preparation will induce activation of helper T-lymphocytes.

Next, after obtaining positive results in the experiments described in 2 above, $P2X_7$-knock out mice will obtained and it will be determined whether they are incapable of mounting a helper or CTL response to IgGrRBCg+ TPHPARIGL+ATP.

The mechanism by which APCs activate helper and cytotoxic lymphocytes to react to peptide antigens, including peptides with altered amino acid sequences from mutated tumor-cell proteins, is central to current immunotherapeutic approaches to cancer. The experiments

herein will provide insight into the cellular mechanism by which apoptotic cells deliver antigenic peptides to Class I MHC of APCs and may uncover a novel and potentially clinically useful protocol for activating cytotoxic and helper T-lymphocytes.

REFERENCES

1. Mellman et al., Trends in Cell Biol. 8:231-237, 1998.

2. MacKenzie et al., Ann. N.Y. Acad. Sci. 868:716-729, 1999.

3. Mutini et al., J. Immunol. 163:1958-1965, 1999.

4. Steinberg et al., J. Biol. Chem. 262:8884-8888, 1987.

5. Coutinho-Silva et al., Am. J. Physiol. 276:C1139-1147, 1999.

6. Fratazzi et al., J. Immunol. 156:679-684, 1997.

7. Zambon et al., Cell Immunol. 156:458-467, 1994.

8. Buckner et al., Eur. J. Immunol. 27:2541-2548, 1997.

9. Lin et al., Cancer Res. 50:2808-2817, 1990.

What is claimed is:

1. A method of delivering an antigen to an Class I MHC receptor to induce immunity against the antigen in a subject having a disease which comprises:

a) filling particles with the antigen and ATP resulting in an antigen- and ATP-filled particles (Ag/ATP-filled particles);

b) coating the Ag/ATP-filled particles of step (a) with a ligand for an antigen presenting cell resulting in a ligand-coated Ag/ATP-filled particles;

c) incubating the ligand-coated Ag/ATP-filled particles of step (b) with isolated ligand-binding antigen presenting cells (APCs) under conditions permitting the ligand-binding APCs to bind to the ligand-coated Ag/ATP-filled particles and APC phagolysosomes to ingest the ligand-coated Ag/ATP-filled particles to facilitate transfer of the ingested antigen from the phagolysosomes into cytoplasm such that the antigen is delivered to a Class I MHC receptor and is expressed on the surface of the APCs (Ag-APCs); and

d) administering the antigen presenting cells (APCs) of step (c) to a subject having the disease so as induce Class I MHC presentation and elicit cytotoxic T-lymphocytes against the antigen, thereby inducing immunity against the antigen.

2. The method of claim 1, wherein the particle is a type O red blood cell ghost.

3. The method of claim 1, wherein the particle is a liposome.

4. The method of claim 1, wherein the ligand is selected from the group consisting of an immunoglobulin (IgG), complement component C3b, complement component C3bi, maleic anhydride, an oxidized lipid, a sugar, and a polyanion.

5. The method of claim 1, wherein the antigen presenting cell is selected from the group consisting of a dendritic cell, a Langerhans cell, a monocyte, a mononuclear phagocyte, a macrophage, a Kupfer cell, a microglial cell, an osteoclast, and a bone marrow-derived leukocyte.

6. The method of claim 1, wherein the antigen is a purified antigen.

7. The method of claim 6, wherein the antigen is a cancer cell antigen, a bacterial antigen or a viral antigen.

8. The method of claim 1, wherein the antigen is a crude cell extract.

9. The method of claim 8, wherein the antigen is a cancer cell antigen, a bacterial antigen or a viral

antigen.

10. The method of claim 6, wherein the antigen is selected from the group consisting of a peptide, a carbohydrate, a lipid, a glycoprotein, a glycolipid and a lipoprotein.

11. The method of claim 1 further comprising delivering at least one stimulatory cytokine with the antigen to the cytoplasmic matrix of an antigen presenting cell which comprises in step (a) filling the particle with the stimulatory cytokine.

12. The method of claim 11, wherein the cytokine is IL-12, G-CSF, IL-4, GM-CSF or interferon gamma.

13. The method of claim 1, wherein the immunity induced is against a bacterial or viral antigen.

14. The method of claim 1, wherein the immunity induced is against a cancerous tumor.

15. The method of claim 1, wherein the disease is a bacterial infection or a viral infection.

16. The method of claim 1, wherein the disease is cancer.

17. A method of delivering an antigen to an Class I MHC receptor to induce immunity against the antigen in a subject having a disease which comprises:

a) filling particles with the antigen and ATP resulting in an antigen- and ATP-filled particles (Ag/ATP-filled particles);

b) coating the Ag/ATP-filled particles of step (a) with a ligand for an antigen presenting cell resulting in a ligand-coated Ag/ATP-filled particles;

c) incubating the ligand-coated Ag/ATP-filled particles of step (b) with isolated ligand-binding antigen presenting cells (APCs) under conditions permitting the ligand-binding APCs to bind to the ligand-coated Ag/ATP-filled particles and APC phagolysosomes to ingest the ligand-coated Ag/ATP-filled particles to facilitate transfer of the ingested antigen from the phagolysosomes into cytoplasm such that the antigen is delivered to a Class I MHC receptor and is expressed on the surface of the APCs (Ag-APCs);

d) incubating the Ag-APCs of step (c) with lymphocytes previously removed from the subject having the disease; and

e) administering the incubated lymphocytes of step (d) to the subject so to induce immunity against the antigen in the subject.

18. The method of claim 17, wherein the particle is a type O red blood cell ghost.

19. The method of claim 17, wherein the particle is a liposome.

20. The method of claim 17, wherein the ligand is selected from the group consisting of an immunoglobulin (IgG), complement component C3b, complement component C3bi, maleic anhydride, an oxidized lipid, a sugar, and a polyanion.

21. The method of claim 17, wherein the antigen presenting cell is selected from the group consisting of a dendritic cell, a Langerhans cell, a monocyte, a mononuclear phagocyte, a macrophage, a Kupfer cell, a microglial cell, an osteoclast, and a bone marrow-derived leukocyte.

22. The method of claim 17, wherein the antigen is a purified antigen.

23. The method of claim 22, wherein the antigen is a cancer cell antigen, a bacterial antigen or a viral antigen.

24. The method of claim 17, wherein the antigen is a crude cell extract.

25. The method of claim 24, wherein the antigen is a cancer cell antigen, a bacterial antigen or a viral antigen.

26. The method of claim 22, wherein the antigen is selected from the group consisting of a peptide, a carbohydrate, a lipid, a glycoprotein, a glycolipid

and a lipoprotein.

27. The method of claim 17 further comprising delivering at least one stimulatory cytokine with the antigen to the cytoplasmic matrix of an antigen presenting cell which comprises in step (a) filling the particle with the stimulatory cytokine.

28. The method of claim 27, wherein the cytokine is IL-12, G-CSF, IL-4, GM-CSF or interferon gamma.

29. The method of claim 17, wherein the immunity induced is against a bacterial or viral antigen.

30. The method of claim 17, wherein the immunity induced is against a cancerous tumor.

31. The method of claim 17, wherein the disease is a bacterial infection or a viral infection.

32. The method of claim 17, wherein the disease is cancer.

33. A method of delivering an antigen to an Class II MHC receptor to induce immunity against the antigen in a subject having a disease which comprises:

a) filling particles with the antigen and ATP resulting in an antigen- and ATP-filled particles (Ag/ATP-filled particles);

b) coating the Ag/ATP-filled particles of step (a) with a ligand for an antigen presenting

cell resulting in a ligand-coated Ag/ATP-filled particles;

c) incubating the ligand-coated Ag/ATP-filled particles of step (b) with isolated ligand-binding antigen presenting cells (APCs) under conditions permitting the ligand-binding APCs to bind to the ligand-coated Ag/ATP-filled particles and APC phagolysosomes to ingest the ligand-coated Ag/ATP-filled particles to facilitate transfer of the ingested antigen from the phagolysosomes into cytoplasm such that the antigen is delivered to a Class II MHC receptor and is expressed on the surface of the APCs (Ag-APCs); and

d) administering the antigen presenting cells (APCs) of step (c) to a subject having the disease so as induce Class II MHC presentation and elicit helper T-lymphocytes against the antigen, thereby inducing immunity against the antigen.

34. The method of claim 33, wherein the particle is a type O red blood cell ghost.

35. The method of claim 33, wherein the particle is a liposome.

36. The method of claim 33, wherein the ligand is selected from the group consisting of an immunoglobulin (IgG), complement component C3b, complement component C3bi, maleic anhydride, an

oxidized lipid, a sugar, and a polyanion.

37. The method of claim 33, wherein the antigen presenting cell is selected from the group consisting of a dendritic cell, a Langerhans cell, a monocyte, a mononuclear phagocyte, a macrophage, a Kupfer cell, a microglial cell, an osteoclast, and a bone marrow-derived leukocyte.

38. The method of claim 33, wherein the antigen is a purified antigen.

39. The method of claim 38, wherein the antigen is a cancer cell antigen, a bacterial antigen or a viral antigen.

40. The method of claim 33, wherein the antigen is a crude cell extract.

41. The method of claim 40, wherein the antigen is a cancer cell antigen, a bacterial antigen or a viral antigen.

42. The method of claim 38, wherein the antigen is selected from the group consisting of a peptide, a carbohydrate, a lipid, a glycoprotein, a glycolipid and a lipoprotein.

43. The method of claim 33 further comprising delivering at least one stimulatory cytokine with the antigen to the cytoplasmic matrix of an antigen presenting

cell which comprises in step (a) filling the particle with the stimulatory cytokine.

44. The method of claim 43, wherein the cytokine is IL-12, G-CSF, IL-4, GM-CSF or interferon gamma.

45. The method of claim 33, wherein the immunity induced is against a bacterial or viral antigen.

46. The method of claim 33, wherein the immunity induced is against a cancerous tumor.

47. The method of claim 33, wherein the disease is a bacterial infection or a viral infection.

48. The method of claim 33, wherein the disease is cancer.

49. A method of delivering an antigen to an Class II MHC receptor to induce immunity against the antigen in a subject having a disease which comprises:

a) filling particles with the antigen and ATP resulting in an antigen- and ATP-filled particles (Ag/ATP-filled particles);

b) coating the Ag/ATP-filled particles of step (a) with a ligand for an antigen presenting cell resulting in a ligand-coated Ag/ATP-filled particles;

c) incubating the ligand-coated Ag/ATP-filled particles of step (b) with isolated ligand-binding antigen presenting cells (APCs) under

conditions permitting the ligand-binding APCs to bind to the ligand-coated Ag/ATP-filled particles and APC phagolysosomes to ingest the ligand-coated Ag/ATP-filled particles to facilitate transfer of the ingested antigen from the phagolysosomes into cytoplasm such that the antigen is delivered to a Class I MHC receptor and is expressed on the surface of the APCs (Ag-APCs);

d) incubating the Ag-APCs of step (c) with lymphocytes previously removed from the subject having the disease; and

e) administering the incubated lymphocytes of step (d) to the subject so as induce Class II MHC presentation and elicit helper T-lymphocytes so to induce immunity against the antigen in the subject.

50. The method of claim 49, wherein the particle is a type O red blood cell ghost.

51. The method of claim 49, wherein the particle is a liposome.

52. The method of claim 49, wherein the ligand is selected from the group consisting of an immunoglobulin (IgG), complement component C3b, complement component C3bi, maleic anhydride, an oxidized lipid, a sugar, and a polyanion.

53. The method of claim 49, wherein the antigen

presenting cell is selected from the group consisting of a dendritic cell, a Langerhans cell, a monocyte, a mononuclear phagocyte, a macrophage, a Kupfer cell, a microglial cell, an osteoclast, and a bone marrow-derived leukocyte.

54. The method of claim 49, wherein the antigen is a purified antigen.

55. The method of claim 52, wherein the antigen is a cancer cell antigen, a bacterial antigen or a viral antigen.

56. The method of claim 49, wherein the antigen is a crude cell extract.

57. The method of claim 56, wherein the antigen is a cancer cell antigen, a bacterial antigen or a viral antigen.

58. The method of claim 49, wherein the antigen is selected from the group consisting of a peptide, a carbohydrate, a lipid, a glycoprotein, a glycolipid and a lipoprotein.

59. The method of claim 49, further comprising delivering at least one stimulatory cytokine with the antigen to the cytoplasmic matrix of an antigen presenting cell which comprises in step (a) filling the particle with the stimulatory cytokine.

60. The method of claim 59, wherein the cytokine is IL-12, G-CSF, IL-4, GM-CSF or interferon gamma.

61. The method of claim 49, wherein the immunity induced is against a bacterial or viral antigen.

62. The method of claim 49, wherein the immunity induced is against a cancerous tumor.

63. The method of claim 49, wherein the disease is a bacterial infection or a viral infection.

64. The method of claim 49, wherein the disease is cancer.

65. A method of delivering an antigen to an Class II MHC receptor to supress immunity against the antigen in a subject having a disease which comprises:

a) filling particles with the antigen and ATP resulting in an antigen- and ATP-filled particles (Ag/ATP-filled particles);

b) coating the Ag/ATP-filled particles of step (a) with a ligand for an antigen presenting cell resulting in a ligand-coated Ag/ATP-filled particles;

c) incubating the ligand-coated Ag/ATP-filled particles of step (b) with isolated ligand-binding antigen presenting cells (APCs) under conditions permitting the ligand-binding APCs to bind to the ligand-coated Ag/ATP-filled particles and APC phagolysosomes to ingest the

ligand-coated Ag/ATP-filled particles to facilitate transfer of the ingested antigen from the phagolysosomes into cytoplasm such that the antigen is delivered to a Class II MHC receptor and is expressed on the surface of the APCs (Ag-APCs);

d) incubating the Ag-APCs of step (c) with lymphocytes previously removed from the subject having the disease; and

e) administering the incubated lymphocytes of step (d) to the subject so as induce Class II MHC presentation and elicit suppressor T-lymphocytes so to supress immunity against the antigen in the subject.

66. The method of claim 65, wherein the particle is a type O red blood cell ghost.

67. The method of claim 65, wherein the particle is a liposome.

68. The method of claim 65, wherein the ligand is selected from the group consisting of an immunoglobulin (IgG), complement component C3b, complement component C3bi, maleic anhydride, an oxidized lipid, a sugar, and a polyanion.

69. The method of claim 65, wherein the antigen presenting cell is selected from the group consisting of a dendritic cell, a Langerhans cell, a monocyte, a mononuclear phagocyte, a macrophage,

a Kupfer cell, a microglial cell, an osteoclast, and a bone marrow-derived leukocyte.

70. The method of claim 65, wherein the antigen is a purified antigen.

71. The method of claim 70, wherein the antigen is an antigen of a transplant organ.

72. The method of claim 71, wherein the transplant organ antigen is allogeneic antigen, a syngeneic antigen, or a xenogenic antigen.

73. The method of claim 65, wherein the antigen is a crude cell extract.

74. The method of claim 73, wherein the antigen is an antigen of a transplant organ.

75. The method of claim 74, wherein the transplant organ antigen is allogeneic antigen, a syngeneic antigen, or a xenogenic antigen.

76. The method of claim 65, wherein the antigen is selected from the group consisting of a peptide, a carbohydrate, a lipid, a glycoprotein, a glycolipid and a lipoprotein.

77. The method of claim 65, further comprising delivering at least one stimulatory cytokine with the antigen to the cytoplasmic matrix of an antigen

presenting cell which comprises in step (a) filling the particle with the stimulatory cytokine.

78. The method of claim 77, wherein the cytokine is IL-12, G-CSF, IL-4, GM-CSF or interferon gamma.

79. The method of claim 65, wherein the immunity suppressed is immunity against a transplanted organ or tissue.

80. The method of claim 65, wherein the immunity suppressed is immunity against organs of the subject.

81. The method of claim 65, wherein the disease is an autoimmune disease or rejection of a transplanted organ or tissue.

82. A method of delivering an antigen to an Class I MHC receptor to supress immunity against the antigen in a subject having a disease which comprises:

a) filling particles with the antigen and ATP resulting in an antigen- and ATP-filled particles (Ag/ATP-filled particles);

b) coating the Ag/ATP-filled particles of step (a) with a ligand for an antigen presenting cell resulting in a ligand-coated Ag/ATP-filled particles;

c) incubating the ligand-coated Ag/ATP-filled particles of step (b) with isolated ligand-binding antigen presenting cells (APCs) under

conditions permitting the ligand-binding APCs to bind to the ligand-coated Ag/ATP-filled particles and APC phagolysosomes to ingest the ligand-coated Ag/ATP-filled particles to facilitate transfer of the ingested antigen from the phagolysosomes into cytoplasm such that the antigen is delivered to a Class I MHC receptor and is expressed on the surface of the APCs (Ag-APCs);

d) incubating the Ag-APCs of step (c) with lymphocytes previously removed from the subject having the disease; and

e) administering the incubated lymphocytes of step (d) to the subject so as induce Class I MHC presentation and elicit suppressor T-lymphocytes so to supress immunity against the antigen in the subject.

83. The method of claim 82, wherein the particle is a type O red blood cell ghost.

84. The method of claim 82, wherein the particle is a liposome.

85. The method of claim 82, wherein the ligand is selected from the group consisting of an immunoglobulin (IgG), complement component C3b, complement component C3bi, maleic anhydride, an oxidized lipid, a sugar, and a polyanion.

86. The method of claim 82, wherein the antigen

presenting cell is selected from the group consisting of a dendritic cell, a Langerhans cell, a monocyte, a mononuclear phagocyte, a macrophage, a Kupfer cell, a microglial cell, an osteoclast, and a bone marrow-derived leukocyte.

87. The method of claim 82, wherein the antigen is a purified antigen.

88. The method of claim 87, wherein the antigen is an antigen of a transplant organ.

89. The method of claim 88, wherein the transplant organ antigen is allogeneic antigen, a syngeneic antigen, or a xenogenic antigen.

90. The method of claim 82, wherein the antigen is a crude cell extract.

91. The method of claim 90, wherein the antigen is an antigen of a transplant organ.

92. The method of claim 91, wherein the transplant organ antigen is allogeneic antigen, a syngeneic antigen, or a xenogenic antigen.

93. The method of claim 82, wherein the antigen is selected from the group consisting of a peptide, a carbohydrate, a lipid, a glycoprotein, a glycolipid and a lipoprotein.

94. The method of claim 82, further comprising delivering at least one stimulatory cytokine with the antigen to the cytoplasmic matrix of an antigen presenting cell which comprises in step (a) filling the particle with the stimulatory cytokine.

95. The method of claim 94, wherein the cytokine is IL-12, G-CSF, IL-4, GM-CSF or interferon gamma.

96. The method of claim 82, wherein the immunity suppressed is immunity against a transplanted organ or tissue.

97. The method of claim 82, wherein the immunity suppressed is immunity against organs of the subject.

98. The method of claim 82, wherein the disease is an autoimmune disease or rejection of a transplanted organ or tissue.

99. A method of delivering an antigen to an Class I MHC receptor to supress immunity against the antigen in a subject having a disease which comprises:

a) filling particles with the antigen and ATP resulting in an antigen- and ATP-filled particles (Ag/ATP-filled particles);

b) coating the Ag/ATP-filled particles of step (a) with a ligand for an antigen presenting cell resulting in a ligand-coated Ag/ATP-filled particles;

c) incubating the ligand-coated Ag/ATP-filled particles of step (b) with isolated ligand-binding antigen presenting cells (APCs) under conditions permitting the ligand-binding APCs to bind to the ligand-coated Ag/ATP-filled particles and APC phagolysosomes to ingest the ligand-coated Ag/ATP-filled particles to facilitate transfer of the ingested antigen from the phagolysosomes into cytoplasm such that the antigen is delivered to a Class I MHC receptor and is expressed on the surface of the APCs (Ag-APCs); and

d) administering the antigen presenting cells (APCs) of step (c) to a subject having the disease so as induce Class I MHC presentation and elicit suppressor T-lymphocytes so to supress immunity against the antigen in the subject.

100. The method of claim 99, wherein the particle is a type O red blood cell ghost.

101. The method of claim 99, wherein the particle is a liposome.

102. The method of claim 99, wherein the ligand is selected from the group consisting of an immunoglobulin (IgG), complement component C3b, complement component C3bi, maleic anhydride, an oxidized lipid, a sugar, and a polyanion.

103. The method of claim 99, wherein the antigen presenting cell is selected from the group consisting of a dendritic cell, a Langerhans cell, a monocyte, a mononuclear phagocyte, a macrophage, a Kupfer cell, a microglial cell, an osteoclast, and a bone marrow-derived leukocyte.

104. The method of claim 99, wherein the antigen is a purified antigen.

105. The method of claim 104, wherein the antigen is an antigen of a transplant organ.

106. The method of claim 105, wherein the transplant organ antigen is allogeneic antigen, a syngeneic antigen, or a xenogenic antigen.

107. The method of claim 99, wherein the antigen is a crude cell extract.

108. The method of claim 107, wherein the antigen is an antigen of a transplant organ.

109. The method of claim 108, wherein the transplant organ antigen is allogeneic antigen, a syngeneic antigen, or a xenogenic antigen.

110. The method of claim 99, wherein the antigen is selected from the group consisting of a peptide, a carbohydrate, a lipid, a glycoprotein, a glycolipid and a lipoprotein.

111. The method of claim 99, further comprising delivering at least one stimulatory cytokine with the antigen to the cytoplasmic matrix of an antigen presenting cell which comprises in step (a) filling the particle with the stimulatory cytokine.

112. The method of claim 111, wherein the cytokine is IL-12, G-CSF, IL-4, GM-CSF or interferon gamma.

113. The method of claim 99, wherein the immunity suppressed is immunity against a transplanted organ or tissue.

114. The method of claim 99, wherein the immunity suppressed is immunity against organs of the subject.

115. The method of claim 99, wherein the disease is an autoimmune disease or rejection of a transplanted organ or tissue.

116. A method of delivering an antigen to an Class II MHC receptor to supress immunity against the antigen in a subject having a disease which comprises:

a) filling particles with the antigen and ATP resulting in an antigen- and ATP-filled particles (Ag/ATP-filled particles);

b) coating the Ag/ATP-filled particles of step (a) with a ligand for an antigen presenting cell resulting in a ligand-coated Ag/ATP-

filled particles;

c) incubating the ligand-coated Ag/ATP-filled particles of step (b) with isolated ligand-binding antigen presenting cells (APCs) under conditions permitting the ligand-binding APCs to bind to the ligand-coated Ag/ATP-filled particles and APC phagolysosomes to ingest the ligand-coated Ag/ATP-filled particles to facilitate transfer of the ingested antigen from the phagolysosomes into cytoplasm such that the antigen is delivered to a Class II MHC receptor and is expressed on the surface of the APCs (Ag-APCs); and

d) administering the antigen presenting cells (APCs) of step (c) to a subject having the disease so as induce Class II MHC presentation and elicit suppressor T-lymphocytes so to supress immunity against the antigen in the subject.

117. The method of claim 116, wherein the particle is a type O red blood cell ghost.

118. The method of claim 116, wherein the particle is a liposome.

119. The method of claim 116, wherein the ligand is selected from the group consisting of an immunoglobulin (IgG), complement component C3b, complement component C3bi, maleic anhydride, an oxidized lipid, a sugar, and a polyanion.

120. The method of claim 116, wherein the antigen presenting cell is selected from the group consisting of a dendritic cell, a Langerhans cell, a monocyte, a mononuclear phagocyte, a macrophage, a Kupfer cell, a microglial cell, an osteoclast, and a bone marrow-derived leukocyte.

121. The method of claim 116, wherein the antigen is a purified antigen.

122. The method of claim 121, wherein the antigen is an antigen of a transplant organ.

123. The method of claim 122, wherein the transplant organ antigen is allogeneic antigen, a syngeneic antigen, or a xenogenic antigen.

124. The method of claim 116, wherein the antigen is a crude cell extract.

125. The method of claim 124, wherein the antigen is an antigen of a transplant organ.

126. The method of claim 125, wherein the transplant organ antigen is allogeneic antigen, a syngeneic antigen, or a xenogenic antigen.

127. The method of claim 116, wherein the antigen is selected from the group consisting of a peptide, a carbohydrate, a lipid, a glycoprotein, a glycolipid

and a lipoprotein.

128. The method of claim 116, further comprising delivering at least one stimulatory cytokine with the antigen to the cytoplasmic matrix of an antigen presenting cell which comprises in step (a) filling the particle with the stimulatory cytokine.

129. The method of claim 128, wherein the cytokine is IL-12, G-CSF, IL-4, GM-CSF or interferon gamma.

130. The method of claim 116, wherein the immunity suppressed is immunity against a transplanted organ or tissue.

131. The method of claim 116, wherein the immunity suppressed is immunity against organs of the subject.

132. The method of claim 116, wherein the disease is an autoimmune disease or rejection of a transplanted organ or tissue.

Abstract of the Disclosure

This invention provides methods of delivering an antigen to an Class I or Class II MHC receptors to induce immunity against the antigen in a subject having a disease. This invention also provides methods of delivering an antigen to an Class II or class I MHC receptor to supress immunity against the antigen in a subject having a disease. the ligand-binding APCs to bind to the ligand-coated Ag/ATP-filled particles and APC phagolysosomes to ingest the ligand-coated Ag/ATP-filled particles to facilitate transfer of the ingested antigen from the phagolysosomes into cytoplasm such that the antigen is delivered to a Class II MHC receptor and is expressed on the surface of the APCs (Ag-APCs); d) incubating the Ag-APCs of step (c) with lymphocytes previously removed from the subject having the disease; and e) administering the incubated lymphocytes of step (d) to the subject so as induce Class II MHC presentation and elicit suppressor T-lymphocytes so to supress immunity against the antigen in the subject.

Figure 1



Figure 2



LY Fluorescence image

Phase image

24 h incubation with LY E(IgG)

Figure 3



Figure 4A

J774 cells that have ingested IgGrRBCg +LY+ATP



Fluorescence

Phase

Figure 4B

Fig 1b. J774 cell that have ingested IgGrRBCg +LY



Fluorescence

Phase

DECLARATION AND POWER OF ATTORNEY

As a below-named inventor, I hereby declare that: we, Samuel C. Silverstein, John D. Loike and Francesco DiVirgilio

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

A NOVEL METHOD FOR USING PHAGOCYTIC PARTICLES AND ATP RECEPTORS TO DELIVER ANTIGENS TO MHC CLASS I RECEPTORS TO INDUCE IMMUNITY AGAINST MICROBIAL PATHOGENS OR TUMORS OR TO SUPPRESS IMMUNITY

the specification of which:
(check one)

X *is attached hereto.*

X *was filed on* September 8, 2000 *as*

Application Serial No _____

and was amended _____
(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119 (a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International Application which designated at least one country other than the United States, listed below. I have also identified below any foreign application for patent or inventor's certificate, or PCT International Application having a filing date before that of the earliest application from which priority is claimed:

Prior Foreign Application(s) *Priority Claimed*

Number	*Country*	*Filing Date*	*Yes*	*No*
N/A				

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below:

Provisional Application No.	*Filing Date*	*Status*
N/A		

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States Application(s), or Section 365(c) of any PCT International Application(s) designating the United States listed below. Insofar as this application discloses and claims subject matter in addition to that disclosed in any such prior Application in the manner provided by the first paragraph of Title 35, United States Code, Section 112. I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56, which became available between the filing date(s) of such prior Application(s) and the national or PCT international filing date of this application:

Application Serial No.	*Filing Date*	*Status*
N/A		

And I hereby appoint

John P. White (Reg. No. 28,678); Christopher C. Dunham (Reg. No. 22,031); Norman H. Zivin (Reg. No. 25,385); Jay H. Maioli (Reg. No. 27,213); William E. Pelton (Reg. No. 25,702); Robert D. Katz (Reg. No. 30,141); Peter J. Phillips (Reg. No. 29,691); Wendy E. Miller (Reg. No. 35,615); Richard S. Milner (Reg. No. 33,970); Robert T. Maldonado (Reg. 38,232); Paul Teng (40,837); Richard F. Jaworski (Reg. No. 33,515); Elizabeth M. Wieckowski (Reg. No. 42,226); Pedro C. Fernandez (Reg. No. 41,741); Gary J. Gershik (Reg. No. 39,992); Jane M. Love (Reg. No. 42,812); Spencer H. Schneider (Reg. No. 45,923) and Raymond A. Diperna (Reg. No. 44,063).

and each of them, all c/o Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, New York 10036, my attorneys, each with full power of substitution and revocation, to prosecute this application, to make alterations and amendments therein, to receive the patent, to transact all business in the Patent and Trademark Office connected therewith and to file any International Applications which are based thereon under the provisions of the Patent Cooperation Treaty.

Please address all communications, and direct all telephone calls, regarding this application to.

John P. White, Esq. *Reg. No.* 28,678
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
Tel. (212) 278-0400

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first joint inventor Samuel C. Silverstein

*Inventor's signature*_____

*Citizenship*_____ *Date of signature*_____

*Residence*_____

*Post Office Address*_____

_____

Full name of joint inventor (if any) John D. Loike

*Inventor's signature*_____

*Citizenship*_____ *Date of signature*_____

*Residence*_____

*Post Office Address*_____

_____

Full name of joint inventor (if any) Francesco DiVirgilio

*Inventor's signature*_____

*Citizenship*_____ *Date of signature*_____

*Residence*_____

*Post Office Address*_____

_____

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division

Application deficiencies were found during scanning:

☐ Page(s)_____ of small entity statement were not present for scanning. (Document title)

☐ Page(s)_____ of _____ were not present for scanning. (Document title)

☒ Scanned copy is best available. Drawings